No Data
No Data
Not Many Are Piling Into Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Just Yet
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) price-to-earnings (or "P/E") ratio of 13.2x might make it look like a buy right now compared to the market in the United States, where around half of th
Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $71
Piper Sandler analyst David Amsellem maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate
Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Needham analyst Serge Belanger maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 42.8% and a total average return of 1.8%
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Capital One Financial analyst Tim Chiang maintains $Amphastar Pharmaceuticals(AMPH.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success r
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) climbed 1
Amphastar Pharmaceuticals Holds Steady Amidst New Approval and Competitive Market
No Data